- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Innate Pharma (IPH)
The Innate Pharma share price today is 1.3420, view EPA IPH stock exchange data. Track the latest Innate Pharma share price with real-time updates on IPH stock performance including market cap, day range, 52-week range and dividend yield. Access IPH charts, earnings dates and analyst estimates to support your investment decisions.
Currency in EUR
1.3420
+0.0220(+1.67%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3400
1.3740
52 wk Range
1.0300
2.3300
IPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.34001.3740
52 wk Range
1.03002.3300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IPH Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
5.9000
Upside
+339.64%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
RSI suggests the stock is in oversold territory
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 5.9000
(+339.64% Upside)
Innate Pharma Earnings Call Summary for Q3/2025
- Innate Pharma reported a €56.4 million cash position with runway through Q3 2026, though stock fell 2.29% following the earnings announcement lacking detailed financial metrics.
- The company is advancing key assets including IPH4502 and Monalizumab, with anticipated data readouts in H1 and H2 2026 respectively.
- CEO Jonathan Dickinson highlighted Lacutamab as a 'game-changer' with potential accelerated approval in 2027 and strategic positioning in the CTCL market.
- Executives expressed confidence in manufacturing capabilities and commercial readiness during Q&A, emphasizing efforts to position Lacutamab within NCCN guidelines.
Last Updated: 13-11-2025, 07:34 pm
Read Full TranscriptEarnings
Latest Release
17-09-2026
EPS / Forecast
-0.21 / -0.21
Revenue / Forecast
5.66M / 7.89M
Compare IPH to Peers and Sector
Metrics to compare | IPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIPHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.6x | −2.5x | −0.3x | |
PEG Ratio | −0.37 | −0.04 | 0.00 | |
Price/Book | −3.1x | 1.5x | 2.6x | |
Price / LTM Sales | 12.6x | 11.1x | 3.0x | |
Upside (Analyst Target) | 347.0% | 241.4% | 58.5% | |
Fair Value Upside | Unlock | 0.4% | 7.1% | Unlock |
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Innate Pharma (IPH) Share Price Today?
The Innate Pharma share price today is 1.3420.
What is the current Innate Pharma (IPH) share price and day range?
As of 06-10-2026, the Innate Pharma share price is 1.3420, with a previous close of 1.3200. The share price has ranged from 1.3400 to 1.3740 today, while the 52-week range spans from 1.0300 to 2.3300.
What Is the Innate Pharma Market Cap?
As of today, Innate Pharma market cap is 125.7500M.
What Is the Innate Pharma (IPH) Share Price Target?
The average 12-month share price target for Innate Pharma is 5.9000, with a high estimate of 6.2 and a low estimate of 5.6. 2 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +339.64% Upside potential.
What Is Innate Pharma's Earnings Per Share (TTM)?
The Innate Pharma EPS (TTM) is -0.5101.
When Is the Next Innate Pharma Earnings Date?
Innate Pharma will release its next earnings report on 05-11-2026.
From a Technical Analysis Perspective, Is IPH a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Innate Pharma Trade On?
Innate Pharma is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Innate Pharma?
The stock symbol for Innate Pharma is "IPH."
How Many Times Has Innate Pharma Stock Split?
Innate Pharma has split 0 times.
How Many Employees Does Innate Pharma Have?
Innate Pharma has 120 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.